Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage

Exclusion Criteria

• •Secondary causes of ICH;
• •Pre-existing moderate-to-severe renal, liver or blood disorders (anaemia \[hemoglobin \<10g/dL\], thrombocytopaenia \[platelet count \<100×109/L\], leucopenia \[white blood cell \<3×109/L\], cirrhosis or severe hepatic dysfunction, renal insufficiency \[estimated glomerular filtration rate (eGFR) \<15mL/min\]);
• •Prior diagnosis of gout, peripheral neuropathy, myopathy, inflammatory bowel disease or chronic diarrhea;
• •Concurrent treatment with regular immune-suppressant (corticosteroids, cyclophosphamide, azathioprine, mycophenolate mofetil, rituximab), moderate-to-strong CYP3A4 inhibitors (atazanavir, clarithromycin, darunavir/ritonavir, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir/ritonavir) or P-glycoprotein inhibitors (cyclosporine, ranolazine);
• •Known allergy, sensitivity or intolerance to colchicine;
• •Contraindications or inability to complete brain MRI or susceptibility weighted imaging (SWI) scans;
• •Pregnancy or breastfeeding;
• •Recent participation in any other interventional study in the past 30 days before enrollment;
• •Not expected to survive the follow-up period;
• •Inability to adhere to study procedures;
• •Any condition in which investigators believe that participating in this study may be harmful to the patient.